{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:34:47Z","timestamp":1791023687758,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.maturitas.2010.02.008","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T05:24:28Z","timestamp":1268803468000},"page":"182-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Treatment of osteoporosis with denosumab"],"prefix":"10.1016","volume":"66","author":[{"given":"E. Michael","family":"Lewiecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"February (6)","key":"10.1016\/j.maturitas.2010.02.008_bib1","first-page":"785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Klibanski","year":"2001","journal-title":"JAMA"},{"issue":"September (9)","key":"10.1016\/j.maturitas.2010.02.008_bib2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"Perspective. How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"March (9156)","key":"10.1016\/j.maturitas.2010.02.008_bib3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"issue":"2A","key":"10.1016\/j.maturitas.2010.02.008_bib4","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1016\/S0002-9343(97)90022-X","article-title":"The crippling consequences of fractures and their impact on quality of life","volume":"103","author":"Cooper","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.maturitas.2010.02.008_bib5","series-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","author":"World Health Organisation","year":"1994"},{"issue":"January (1)","key":"10.1016\/j.maturitas.2010.02.008_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","article-title":"Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference","volume":"11","author":"Baim","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.maturitas.2010.02.008_bib7","unstructured":"World Health Organization. FRAX WHO fracture risk assessment tool. World Health Organization, 2009; Available from: http:\/\/www.shef.ac.uk\/FRAX\/ [cited 2009 Nov 1]."},{"key":"10.1016\/j.maturitas.2010.02.008_bib8","unstructured":"Kanis JA, on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK: Printed by the University of Sheffield, 2007."},{"key":"10.1016\/j.maturitas.2010.02.008_bib9","series-title":"Clinician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2008"},{"issue":"April (4)","key":"10.1016\/j.maturitas.2010.02.008_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"April (4)","key":"10.1016\/j.maturitas.2010.02.008_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00198-007-0544-4","article-title":"Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)","volume":"19","author":"Fujiwara","year":"2008","journal-title":"Osteoporos Int"},{"issue":"April (2)","key":"10.1016\/j.maturitas.2010.02.008_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jocd.2007.01.001","article-title":"Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment","volume":"10","author":"Siminoski","year":"2007","journal-title":"J Clin Densitom"},{"issue":"February (3)","key":"10.1016\/j.maturitas.2010.02.008_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med"},{"issue":"July (7)","key":"10.1016\/j.maturitas.2010.02.008_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1359\/jbmr.080232","article-title":"Longitudinal trends in use of bone mass measurement among older Americans, 1999\u20132005","volume":"23","author":"Curtis","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"September (9)","key":"10.1016\/j.maturitas.2010.02.008_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/MLR.0b013e3180536764","article-title":"Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure","volume":"45","author":"Foley","year":"2007","journal-title":"Med Care"},{"issue":"July (3)","key":"10.1016\/j.maturitas.2010.02.008_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"issue":"December (12)","key":"10.1016\/j.maturitas.2010.02.008_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int"},{"issue":"December (12)","key":"10.1016\/j.maturitas.2010.02.008_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2010.02.008_bib19","series-title":"Bone health and osteoporosis: a report of the surgeon general","author":"US Department of Health and Human Services","year":"2004"},{"issue":"November (11)","key":"10.1016\/j.maturitas.2010.02.008_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"issue":"March (7)","key":"10.1016\/j.maturitas.2010.02.008_bib21","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"April (2)","key":"10.1016\/j.maturitas.2010.02.008_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"April (2)","key":"10.1016\/j.maturitas.2010.02.008_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"issue":"May (3)","key":"10.1016\/j.maturitas.2010.02.008_bib24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"issue":"July (1)","key":"10.1016\/j.maturitas.2010.02.008_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1210\/endo-129-1-421","article-title":"The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84)","volume":"129","author":"Mosekilde","year":"1991","journal-title":"Endocrinology"},{"issue":"August (2)","key":"10.1016\/j.maturitas.2010.02.008_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"issue":"July (4)","key":"10.1016\/j.maturitas.2010.02.008_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"issue":"May (6937)","key":"10.1016\/j.maturitas.2010.02.008_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"July (7)","key":"10.1016\/j.maturitas.2010.02.008_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"February (8)","key":"10.1016\/j.maturitas.2010.02.008_bib30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"August","key":"10.1016\/j.maturitas.2010.02.008_bib31","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"August (2)","key":"10.1016\/j.maturitas.2010.02.008_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2010.02.008_bib33","unstructured":"Miller P, Bolognese M, Lewiecki E, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 years results of a phase 2 clinical trial. J Bone Miner Res 2009 [cited 2009 Oct 23];24(Suppl 1). Available from: http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=1cf516b5-29be-4edf-b1ed-7fa92b4f2031."},{"issue":"August (8)","key":"10.1016\/j.maturitas.2010.02.008_bib34","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"June (6)","key":"10.1016\/j.maturitas.2010.02.008_bib35","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"January (1)","key":"10.1016\/j.maturitas.2010.02.008_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.maturitas.2010.02.008_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"December","key":"10.1016\/j.maturitas.2010.02.008_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.0105-2896.2005.00334.x","article-title":"The role of the immune system in the pathophysiology of osteoporosis","volume":"208","author":"Clowes","year":"2005","journal-title":"Immunol Rev"},{"issue":"December","key":"10.1016\/j.maturitas.2010.02.008_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.0105-2896.2005.00336.x","article-title":"Osteoclast precursors, RANKL\/RANK, and immunology","volume":"208","author":"Xing","year":"2005","journal-title":"Immunol Rev"},{"issue":"September (18)","key":"10.1016\/j.maturitas.2010.02.008_bib40","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"issue":"January (6717)","key":"10.1016\/j.maturitas.2010.02.008_bib41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"issue":"December (11)","key":"10.1016\/j.maturitas.2010.02.008_bib42","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.4049\/jimmunol.179.11.7497","article-title":"Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses","volume":"179","author":"Stolina","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.maturitas.2010.02.008_bib43","first-page":"S708","article-title":"Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function","volume":"20","author":"Stolina","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.maturitas.2010.02.008_bib44","unstructured":"Reid I, Benhamou CL, Bolognese M, et al. Effects of denosumab on bone histology and histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2009 [cited 2009 Nov 14];24(Suppl 1). Available from: http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=1778e37e-cc4c-482c-a20d-6ae66570d65d."},{"key":"10.1016\/j.maturitas.2010.02.008_bib45","unstructured":"United States Food and Drug Administration, Amgen Inc. Briefing Information for the August 13, 2009 Meeting of the Reproductive Health Drugs Advisory Committee. United States Department of Health & Human Services 2009 [cited 2009 Oct 30]. Available from: http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/ucm176584.htm."},{"issue":"4","key":"10.1016\/j.maturitas.2010.02.008_bib46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/17455057.2.4.517","article-title":"Denosumab: a promising drug for the prevention and treatment of osteoporosis","volume":"2","author":"Lewiecki","year":"2006","journal-title":"Women's Health"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512210000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512210000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:49:09Z","timestamp":1759913349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512210000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0378512210000757"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2010.02.008","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of osteoporosis with denosumab","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2010.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}